Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

GMED

Globus Medical Inc

May 02 • 04:00PM ET

50.48

Dollar change +0.05
Percentage change 0.10	%

Healthcare • Medical Devices • USA • NYSE

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IJH VB VXF VBK IHI IJJ SCHA IWR VHT

Index	-	P/E	43.35	EPS (ttm)	1.16	Insider Own	17.25%	Shs Outstand	113.91M	Perf Week	0.22%
Market Cap	6.83B	Forward P/E	15.28	EPS next Y	3.30	Insider Trans	-0.08%	Shs Float	112.02M	Perf Month	-3.55%
Income	122.87M	PEG	2.68	EPS next Q	0.57	Inst Own	80.68%	Short Float	6.70%	Perf Quarter	-3.81%
Sales	1.57B	P/S	4.36	EPS this Y	16.01%	Inst Trans	1.59%	Short Ratio	7.42	Perf Half Y	10.44%
Book/sh	29.32	P/B	1.72	EPS next Y	22.76%	ROA	3.43%	Short Interest	7.51M	Perf Year	-10.62%
Cash/sh	3.82	P/C	13.20	EPS next 5Y	16.20%	ROE	4.20%	52W Range	43.38 - 62.88	Perf YTD	-5.27%
Dividend Est.	-	P/FCF	41.36	EPS past 5Y	-7.04%	ROI	2.73%	52W High	-19.72%	Beta	1.08
Dividend TTM	-	Quick Ratio	2.72	Sales past 5Y	18.43%	Gross Margin	61.80%	52W Low	16.35%	ATR (14)	1.19
Dividend Ex-Date	-	Current Ratio	4.88	EPS Y/Y TTM	-37.55%	Oper. Margin	13.04%	RSI (14)	42.64	Volatility	1.94% 2.21%
Employees	5000	Debt/Eq	0.13	Sales Y/Y TTM	53.34%	Profit Margin	7.83%	Recom	2.29	Target Price	64.89
Option/Short	Yes / Yes	LT Debt/Eq	0.13	EPS Q/Q	-77.91%	Payout	0.00%	Rel Volume	0.70	Prev Close	50.43
Sales Surprise	1.28%	EPS Surprise	2.70%	Sales Q/Q	124.60%	Earnings	May 07 AMC	Avg Volume	1.01M	Price	50.48
SMA20	-1.86%	SMA50	-4.36%	SMA200	-3.48%	Trades		Volume	704,586	Change	0.10%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-18-24	Upgrade	BTIG Research	Neutral → Buy	$60
Oct-20-23	Initiated	ROTH MKM	Buy	$75
Sep-19-23	Upgrade	Stifel	Hold → Buy	$61
Mar-30-23	Upgrade	Canaccord Genuity	Hold → Buy	$67
Feb-13-23	Downgrade	BofA Securities	Buy → Underperform	$83 → $63
Feb-10-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$67
Feb-10-23	Downgrade	Truist	Buy → Hold	$85 → $70
Feb-10-23	Downgrade	Needham	Buy → Hold
Feb-10-23	Downgrade	Loop Capital	Buy → Hold	$90 → $70
Feb-10-23	Downgrade	BTIG Research	Buy → Neutral
Oct-18-22	Initiated	Barclays	Overweight	$69
Oct-12-22	Initiated	Jefferies	Buy	$75
Apr-13-22	Resumed	Truist	Buy	$80 → $91
Mar-28-22	Initiated	Wells Fargo	Overweight	$80
Jan-04-22	Upgrade	Piper Sandler	Neutral → Overweight	$80 → $88
Dec-13-21	Upgrade	BofA Securities	Underperform → Buy	$55 → $80
Dec-10-21	Initiated	RBC Capital Mkts	Outperform	$80
Oct-29-21	Initiated	Loop Capital	Buy	$100
Feb-18-21	Resumed	Needham	Buy	$65 → $75
Dec-08-20	Initiated	Citigroup	Buy	$72

Show Previous Ratings

Apr-16-24 04:30PM	Globus Medical Schedules First Quarter Earnings Release and Conference Call (GlobeNewswire)
Apr-15-24 09:50AM	Why Globus Medical (GMED) is a Top Momentum Stock for the Long-Term (Zacks)
Apr-04-24 08:41AM	Globus Medical (GMED) Gains From New Launches Amid Macro Issues (Zacks)
Mar-24-24 03:50PM	From Six Figures to Seven: 3 Robotics Stocks Set to Make Millionaires (InvestorPlace)
Mar-21-24 11:30AM	Globus Medical (GMED) Down 5.8% Since Last Earnings Report: Can It Rebound? (Zacks)
04:30PM	Loading…
Mar-13-24 04:30PM	7 Robotic Surgery Stocks to Buy for the Future of Healthcare (InvestorPlace)
12:01PM	Here's Why You Should Retain Globus Medical (GMED) Stock Now (Zacks)
Feb-27-24 09:40AM	Here's Why Globus Medical (GMED) is a Strong Value Stock (Zacks)
Feb-26-24 09:50AM	Here's Why Globus Medical (GMED) is a Strong Momentum Stock (Zacks)
Feb-22-24 03:55AM	11 Best Small-Cap Growth Stocks to Invest In (Insider Monkey)
Feb-21-24 11:45AM	Q4 2023 Globus Medical Inc Earnings Call (Thomson Reuters StreetEvents)
09:45AM	Globus Medical, Inc. (NYSE:GMED) Q4 2023 Earnings Call Transcript (Insider Monkey)
07:13AM	Globus Medical (GMED) Q4 Earnings Surpass, Margins Down (Zacks)
Feb-20-24 08:30PM	Globus Medical (GMED) Q4 2023 Earnings Call Transcript (Motley Fool)
07:00PM	Compared to Estimates, Globus Medical (GMED) Q4 Earnings: A Look at Key Metrics (Zacks)
05:30PM	Loading…
05:30PM	Globus Medical (GMED) Q4 Earnings and Revenues Beat Estimates (Zacks)
04:54PM	Globus Medical Inc (GMED) Posts Record Sales Amid NuVasive Merger, Despite Net Income Dip (GuruFocus.com)
04:40PM	Globus Medical: Q4 Earnings Snapshot (Associated Press Finance)
04:15PM	Globus Medical Reports Fourth Quarter and Full Year 2023 Results (GlobeNewswire)
Feb-14-24 09:15AM	Globus Medical (GMED) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures (Zacks)
Feb-13-24 05:17PM	Globus Medical Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call (GlobeNewswire)
10:00AM	Globus Medical (GMED) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-07-24 05:40AM	Globus Medical names Keith Pfeil as chief operating officer (MedTech Dive)
Feb-05-24 04:30PM	Globus Medical promotes Keith Pfeil to Chief Operating Officer and Chief Financial Officer (GlobeNewswire)
Jan-26-24 06:04AM	Globus lays off Nuvasive employees after merger (MedTech Dive)
Jan-24-24 12:10PM	Will Globus Medical (GMED) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Jan-23-24 08:42AM	Here's Why You Should Retain Globus Medical (GMED) Stock Now (Zacks)
Jan-14-24 12:54PM	7 Healthcare Stocks Taking Medicine to the Next Level (InvestorPlace)
Jan-10-24 04:30PM	Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results (GlobeNewswire)
Dec-29-23 09:33AM	Globus Medical (GMED) Gains From Innovation Amid Macro Issues (Zacks)
05:00AM	Loading…
Dec-19-23 05:00AM	4 Orthobiologic Stocks Set To Soar In 2024 (News Direct)
Dec-15-23 12:14PM	Here's Why You Should Retain Globus Medical (GMED) Stock Now (Zacks)
Dec-10-23 02:31PM	3 Stocks at the Forefront of Medical Robotics (InvestorPlace)
Dec-07-23 11:30AM	Globus Medical (GMED) Down 3.1% Since Last Earnings Report: Can It Rebound? (Zacks)
09:20AM	Globus Medical (GMED) Gains From NuVasive Deal, Macro Woes Stay (Zacks)
Nov-08-23 04:15PM	Globus Medical, Inc. (NYSE:GMED) Q3 2023 Earnings Call Transcript (Insider Monkey)
07:59AM	Globus Medical (GMED) Q3 Earnings Top Estimates, Margins Down (Zacks)
Nov-07-23 08:45PM	Globus Medical (GMED) Q3 2023 Earnings Call Transcript (Motley Fool)
07:00PM	Globus Medical (GMED) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
05:07PM	Globus Medical: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Globus Medical Reports Third Quarter 2023 Results (GlobeNewswire)
Nov-06-23 12:10PM	Why Globus Medical (GMED) is Poised to Beat Earnings Estimates Again (Zacks)
Nov-01-23 10:01AM	Analysts Estimate Silk Road Medical (SILK) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-31-23 10:01AM	Globus Medical (GMED) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-24-23 04:30PM	Globus Medical Schedules Third Quarter Earnings Release and Conference Call (GlobeNewswire)
07:00AM	Five-Year Study Outcomes of the NuVasive Simplify Cervical Disc were Presented at the North American Spine Society 38th Annual Meeting (GlobeNewswire)
Oct-13-23 10:05AM	Globus Medical (GMED) Gains From NuVasive Buyout, Innovation (Zacks)
Oct-10-23 07:00AM	Twenty Years of the NuVasive XLIF Procedure Celebrated at the Society for Minimally Invasive Spine Surgery 2023 Annual Forum (GlobeNewswire)
Oct-05-23 11:40AM	GMED or ABCM: Which Is the Better Value Stock Right Now? (Zacks)
10:09AM	Here's Why You Should Buy Globus Medical (GMED) Stock Now (Zacks)
Oct-03-23 01:03PM	Unveiling the Investment Potential of Globus Medical Inc (GMED): A Comprehensive Analysis of ... (GuruFocus.com)
11:41AM	Unveiling Globus Medical's True Worth: Is It Priced Right? A Comprehensive Guide (GuruFocus.com)
Sep-27-23 07:00AM	Globus Medical and NuVasive to Sponsor and Participate at EUROSPINE 2023 (GlobeNewswire)
Sep-19-23 10:00AM	Dell upgraded, Starbucks downgraded: Wall Street's top analyst calls (The Fly)
01:45AM	Dell a buy on AI and bolstered demand: 5 big analyst picks (Investing.com)
Sep-08-23 12:06PM	Globus Medical (GMED) Launches NuVasive's NSO in Global Market (Zacks)
Sep-07-23 07:00AM	NuVasive Specialized Orthopedics Launches Precice Bone Transport in International Markets (GlobeNewswire)
Sep-04-23 12:48PM	Globus Medical (GMED) Completes NuVasive Merger Agreement (Zacks)
Sep-01-23 08:33AM	Globus Medical Completes Merger with NuVasive (GlobeNewswire)
Aug-28-23 05:41PM	Goosehead Insurance and Jackson Financial Set to Join S&P SmallCap 600 (PR Newswire)
Aug-13-23 05:49PM	15 Worst Performing Healthcare Stocks in 2023 (Insider Monkey)
Aug-05-23 07:03AM	Globus Medical, Inc. (NYSE:GMED) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-04-23 12:26PM	Globus Medical (GMED) Q2 Earnings Beat Estimates, Margins Dip (Zacks)
06:41AM	Q2 2023 Globus Medical Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-03-23 10:00PM	Here's What Key Metrics Tell Us About Globus Medical (GMED) Q2 Earnings (Zacks)
09:30PM	Globus Medical (GMED) Q2 2023 Earnings Call Transcript (Motley Fool)
07:25PM	Globus Medical (GMED) Q2 Earnings and Revenues Surpass Estimates (Zacks)
06:24PM	Globus Medical: Q2 Earnings Snapshot (AP Finance)
04:30PM	Globus Medical Reports Second Quarter 2023 Results (GlobeNewswire)
Jul-31-23 11:13AM	Globus Medical (GMED) Gains on Innovation, Strategic Deal (Zacks)
08:30AM	Globus Medical Announces Launch of the MARVEL Growing Rod System, the companys first product designed specifically for early onset scoliosis (GlobeNewswire)
Jul-26-23 11:40AM	ITGR or GMED: Which Is the Better Value Stock Right Now? (Zacks)
Jul-17-23 09:06AM	Here's Why You Should Retain Globus Medical (GMED) Stock Now (Zacks)
Jul-13-23 04:30PM	Globus Medical Schedules Second Quarter Earnings Release and Conference Call (GlobeNewswire)
01:55PM	CFO of the Year Awards 2023: Keith Pfeil, Globus Medical (American City Business Journals)
Jun-29-23 05:25AM	Globus Medical (GMED) Declined on Investors Concerns Over Merger (Insider Monkey)
Jun-21-23 08:00PM	GMED: What does Argus have to say about GMED? (Argus Research)
Jun-13-23 10:15AM	Globus Medical (GMED) to Gain From NUVA Merger Amid Margin Woe (Zacks)
May-26-23 07:50AM	Here's Why You Should Retain Globus Medical (GMED) Stock Now (Zacks)
May-21-23 10:18AM	Is Globus Medical, Inc. (NYSE:GMED) Potentially Undervalued? (Simply Wall St.)
May-16-23 02:35PM	Globus Medical's (GMED) REFLECT Correction System Gets FDA Nod (Zacks)
May-15-23 04:30PM	Globus Medical Announces FDA Approval for its Non-Fusion Scoliosis Correction System, the Latest Advancement for Young Patients with Idiopathic Scoliosis (GlobeNewswire)
May-05-23 01:23PM	Globus Medical (GMED) Q1 Earnings Beat, Operating Margin Dips (Zacks)
08:16AM	Q1 2023 Globus Medical Inc Earnings Call (Thomson Reuters StreetEvents)
12:30AM	Globus Medical (GMED) Q1 2023 Earnings Call Transcript (Motley Fool)
May-04-23 07:25PM	Globus Medical (GMED) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
04:15PM	Globus Medical Reports First Quarter 2023 Results (GlobeNewswire)
May-03-23 06:45PM	Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
Apr-27-23 07:08PM	Globus Medical Shareholders Approve Share Issuance for Merger with NuVasive (GlobeNewswire)
11:30AM	NuVasive Shareholders Approve Merger Agreement with Globus Medical (PR Newswire)
Apr-26-23 08:00PM	GMED: What does Argus have to say about GMED? (Argus Research)
Apr-24-23 06:48AM	Globus Medical's (NYSE:GMED) investors will be pleased with their 22% return over the last three years (Simply Wall St.)
Apr-19-23 05:15PM	Globus Medical Schedules First Quarter Earnings Release and Conference Call (GlobeNewswire)
Apr-17-23 07:22PM	7 Stocks to Buy with Bulletproof Balance Sheets (InvestorPlace)
01:57PM	Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending NuVasive Shareholders Vote "FOR" the Proposed Merger with Globus Medical (PR Newswire)
Apr-14-23 02:21PM	Leading Independent Proxy Advisory Firm ISS Recommends NuVasive Shareholders Vote "FOR" the Proposed Merger with Globus Medical (PR Newswire)
10:31AM	Globus' (GMED) NUVA Buyout Seems Strategic, Cost Woe Stays (Zacks)
Mar-27-23 12:27PM	Inflation, TikTok, and Other Hot Stories Investors Are Talking About (Motley Fool)
Mar-24-23 10:55AM	Globus Medical (GMED) to Gain From NUVA Deal Amid Rising Costs (Zacks)
Mar-17-23 10:04AM	NuVasive (NUVA), GMED Merger Aids, Macro Woes Mar Growth (Zacks)

Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The firm engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C. Paul, David D. Davidar and Andrew Iott in March 2003 and is headquartered in Audubon, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Norwalk Leslie V	Director	Mar 15 '24	Sale	51.99	10,590	550,574	17,419	Mar 19 07:40 PM
Huller Kelly	SVP, GC, Corporate Secretary	Mar 01 '24	Option Exercise	24.90	7,500	186,750	7,500	Mar 05 05:07 PM
Huller Kelly	SVP, GC, Corporate Secretary	Mar 01 '24	Sale	54.10	7,500	405,730	0	Mar 05 05:07 PM
Lemaitre Dan	Director	May 15 '23	Option Exercise	25.43	43,450	1,104,782	54,250	May 17 04:31 PM
Lemaitre Dan	Director	May 15 '23	Sale	56.98	43,450	2,475,977	10,800	May 17 04:31 PM

Open in Screener

NBIX

Neurocrine Biosciences, Inc.

May 02 • 04:00PM ET

139.83

Dollar change -3.20
Percentage change -2.24	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

NBIX Neurocrine Biosciences, Inc. daily Stock Chart

Held by: IJH VTI VB VXF VBK USMV IBB IJK IWP IWF

Index	-	P/E	38.44	EPS (ttm)	3.64	Insider Own	2.60%	Shs Outstand	98.70M	Perf Week	1.50%
Market Cap	13.91B	Forward P/E	20.68	EPS next Y	6.76	Insider Trans	-22.95%	Shs Float	96.92M	Perf Month	1.63%
Income	369.70M	PEG	2.14	EPS next Q	1.13	Inst Own	92.90%	Short Float	2.09%	Perf Quarter	-1.84%
Sales	1.98B	P/S	7.02	EPS this Y	85.91%	Inst Trans	-1.46%	Short Ratio	2.25	Perf Half Y	26.04%
Book/sh	23.72	P/B	5.90	EPS next Y	47.25%	ROA	12.68%	Short Interest	2.02M	Perf Year	35.17%
Cash/sh	12.17	P/C	11.49	EPS next 5Y	18.00%	ROE	18.16%	52W Range	89.04 - 148.37	Perf YTD	6.12%
Dividend Est.	-	P/FCF	22.65	EPS past 5Y	62.04%	ROI	14.01%	52W High	-5.76%	Beta	0.36
Dividend TTM	-	Quick Ratio	2.47	Sales past 5Y	34.77%	Gross Margin	97.09%	52W Low	57.04%	ATR (14)	4.49
Dividend Ex-Date	Dec 29, 1995	Current Ratio	2.52	EPS Y/Y TTM	458.67%	Oper. Margin	23.73%	RSI (14)	54.48	Volatility	3.45% 2.94%
Employees	1400	Debt/Eq	0.23	Sales Y/Y TTM	23.99%	Profit Margin	18.65%	Recom	1.68	Target Price	154.10
Option/Short	Yes / Yes	LT Debt/Eq	0.11	EPS Q/Q	153.10%	Payout	0.00%	Rel Volume	0.97	Prev Close	143.03
Sales Surprise	0.57%	EPS Surprise	-61.75%	Sales Q/Q	22.57%	Earnings	May 01 BMO	Avg Volume	900.24K	Price	139.83
SMA20	2.36%	SMA50	2.09%	SMA200	14.57%	Trades		Volume	873,642	Change	-2.24%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-24-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$140 → $170
Dec-13-23	Resumed	Citigroup	Neutral	$127
Dec-12-23	Initiated	Deutsche Bank	Buy	$136
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight	$135 → $140
Aug-21-23	Reiterated	Mizuho	Neutral	$112 → $113
Jul-24-23	Upgrade	SVB Securities	Market Perform → Outperform	$115 → $125
Jul-06-23	Upgrade	BMO Capital Markets	Underperform → Market Perform	$91 → $96
May-04-23	Upgrade	Guggenheim	Neutral → Buy	$145
Mar-30-23	Upgrade	Canaccord Genuity	Hold → Buy	$124 → $132
Mar-03-23	Upgrade	Evercore ISI	In-line → Outperform	$130
Feb-03-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$120 → $130
Nov-14-22	Downgrade	Evercore ISI	Outperform → In-line	$140 → $130
Oct-11-22	Initiated	UBS	Buy	$136
Sep-26-22	Initiated	Wells Fargo	Equal Weight	$110
Jun-06-22	Resumed	Jefferies	Buy	$126 → $112
Mar-03-22	Downgrade	Piper Sandler	Overweight → Neutral	$114 → $94
Feb-25-22	Upgrade	Goldman	Neutral → Buy	$115
Jan-18-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$122 → $90
Nov-19-21	Initiated	BMO Capital Markets	Underperform	$76
Nov-17-21	Upgrade	JP Morgan	Neutral → Overweight	$124

Show Previous Ratings

Today 11:18AM	UBS Raises Price Target on Neurocrine Biosciences to $174 From $165, Maintains Buy Rating (MT Newswires)
03:01AM	Neurocrine Biosciences Inc (NBIX) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ... (GuruFocus.com)
01:06AM	Decoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight (GuruFocus.com)
May-01-24 11:36PM	Q1 2024 Neurocrine Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
09:01PM	Neurocrine Biosciences Inc (NBIX) Q1 2024 Earnings: Strong Revenue Growth and Strategic Advancements (GuruFocus.com)
04:18PM	Loading…
04:18PM	Why Things Are Looking Up For IBD Stock Of The Day Neurocrine, A Top 1% Biotech (Investor's Business Daily)
11:54AM	NBIX Stock Earnings: Neurocrine Biosciences Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
09:30AM	Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
09:04AM	No. 1 Biotech Stock Neurocrine Pops After Its Biggest Moneymaker Snatches Another Win (Investor's Business Daily)
08:31AM	Neurocrine Biosciences Swings to Q1 Adjusted Earnings as Revenue Increases -- Shares Jump Pre-Bell (MT Newswires)
08:15AM	Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates (Zacks)
07:18AM	Neurocrine: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Neurocrine Biosciences Reports First Quarter 2024 Financial Results (PR Newswire)
Apr-30-24 05:48PM	REFILE-UPDATE 2-Neurocrine Biosciences' Huntington's disease drug gets FDA approval (April 30) (Reuters)
05:45PM	Neurocrine Gets FDA Approval for Ingrezza Sprinkle Capsules; Shares Rise After-Hours (MT Newswires)
05:31PM	Loading…
05:31PM	FDA approves Neurocrine Biosciences' Huntington's disease drug (Reuters)
05:12PM	Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA SPRINKLE (valbenazine) Capsules (PR Newswire)
09:15AM	Curious about Neurocrine (NBIX) Q1 Performance? Explore Wall Street Estimates for Key Metrics (Zacks)
Apr-24-24 10:15AM	Does Neurocrine, The No. 1 Biotech Stock, Have The Next Ketamine On Its Hands? (Investor's Business Daily)
10:01AM	Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
08:30AM	Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community (PR Newswire)
08:00AM	3 Red-Hot Biotech Rockets Blasting Off in 2024 (InvestorPlace)
Apr-23-24 11:50AM	No. 1 Biotech Stock Neurocrine Launches Higher On Depression Treatment Win (Investor's Business Daily)
07:22AM	Neurocrine scores surprise win with depression drug (BioPharma Dive)
07:00AM	Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder (PR Newswire)
Apr-22-24 11:10AM	10 Best Performing Biotech ETFs in 2024 (Insider Monkey)
Apr-16-24 04:01PM	Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides (GlobeNewswire)
02:30AM	Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568 (GlobeNewswire)
Apr-10-24 04:01PM	Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results (PR Newswire)
Apr-09-24 07:37AM	11 Best Biotech ETFs To Buy (Insider Monkey)
08:30AM	Loading…
Apr-03-24 08:30AM	Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder (PR Newswire)
Mar-28-24 08:30AM	Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults (PR Newswire)
Mar-24-24 09:19AM	Top 12 Stocks in George Soros' Stock Portfolio (Insider Monkey)
Mar-23-24 08:00AM	S&P 500 Giants Lead Five Stocks Near Buy Points With Fed's Powell A Tailwind (Investor's Business Daily)
Mar-16-24 08:00AM	AI Plays HubSpot, Arista Networks Lead Five Stocks Near Buy Points In Classic Base (Investor's Business Daily)
01:23AM	Neurocrine Biosciences Inc's Chief Regulatory Officer Ingrid Delaet Sells 3,000 Shares (GuruFocus.com)
01:23AM	Director Richard Pops Sells 23,200 Shares of Neurocrine Biosciences Inc (NBIX) (GuruFocus.com)
Mar-15-24 10:00AM	Neurocrine Biosciences Is Pioneering Therapies for Neurological Disorders (GuruFocus.com)
Mar-13-24 01:26AM	Director Richard Pops Sells Shares of Neurocrine Biosciences Inc (NBIX) (GuruFocus.com)
Mar-11-24 04:01PM	Neurocrine Biosciences to Participate at Virtual Investor Conferences in March (PR Newswire)
01:12PM	The $1 Billion Opportunity Driving IBD Stock Of The Day Neurocrine Higher (Investor's Business Daily)
Mar-06-24 04:45PM	3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success (InvestorPlace)
Mar-01-24 12:40AM	Neurocrine Biosciences Inc's Chief Regulatory Officer Ingrid Delaet Sells Company Shares (GuruFocus.com)
Feb-27-24 04:01PM	Neurocrine Biosciences to Participate at Investor Conferences in March (PR Newswire)
Feb-22-24 11:28PM	Director Richard Pops Sells 15,000 Shares of Neurocrine Biosciences Inc (GuruFocus.com)
03:55AM	11 Best Small-Cap Growth Stocks to Invest In (Insider Monkey)
Feb-15-24 11:36PM	Neurocrine Biosciences Inc's Chief Commercial Officer Eric Benevich Sells Company Shares (GuruFocus.com)
Feb-10-24 10:18AM	Wall Street Analysts Just Trimmed Price Targets for These 10 Stocks (Insider Monkey)
12:14AM	Decoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight (GuruFocus.com)
Feb-09-24 02:23AM	Neurocrine Biosciences Inc's Chief Commercial Officer Eric Benevich Sells Company Shares (GuruFocus.com)
Feb-08-24 09:13AM	Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q4 2023 Earnings Call Transcript (Insider Monkey)
12:20AM	Q4 2023 Neurocrine Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-07-24 09:30AM	Neurocrine (NBIX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
07:33AM	Neurocrine Biosciences Inc (NBIX) Reports Strong Growth in INGREZZA Sales for Q4 and Full Year 2023 (GuruFocus.com)
07:18AM	Neurocrine: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024 (PR Newswire)
Feb-05-24 09:16AM	Ahead of Neurocrine (NBIX) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics (Zacks)
Feb-02-24 11:02PM	Neurocrine Biosciences Inc CFO Matt Abernethy Sells Company Shares (GuruFocus.com)
Jan-31-24 10:00AM	Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy? (Zacks)
Jan-24-24 11:02PM	Neurocrine Biosciences Inc's Chief Legal Officer Sells Shares (GuruFocus.com)
06:54AM	Neurocrine Biosciences is Under Heavy Accumulation, The One Chart that Matters (FX Empire)
Jan-22-24 09:38AM	Growth Stock Portfolio: 15 Companies with At Least 30% Annual Growth Rates (Insider Monkey)
Jan-17-24 04:16PM	Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2023 Financial Results (PR Newswire)
Jan-12-24 09:35AM	5 High Growth NASDAQ Stocks That Are Profitable (Insider Monkey)
Jan-11-24 09:02PM	Neurocrine Biosciences Inc CEO Kevin Gorman Sells 167,858 Shares (GuruFocus.com)
Jan-10-24 09:24AM	How Neurocrine (NBIX) Stock Stands Out in a Strong Industry (Zacks)
Jan-05-24 02:02AM	Director William Rastetter Sells Shares of Neurocrine Biosciences Inc (NBIX) (GuruFocus.com)
Jan-02-24 04:01PM	Neurocrine Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-26-23 06:56PM	13 High Growth Healthcare Stocks to Buy (Insider Monkey)
07:22AM	Neurocrine (NBIX) Soars 6.0%: Is Further Upside Left in the Stock? (Zacks)
Dec-25-23 08:23PM	3 Stocks at the Forefront of Medical Innovation (InvestorPlace)
Dec-20-23 04:54AM	Here's Why Neurocrine Biosciences (NBIX) Rose in Q3 (Insider Monkey)
Dec-16-23 01:01PM	Insider Sell: Chief Medical Officer Eiry Roberts Sells Shares of Neurocrine Biosciences Inc (GuruFocus.com)
Dec-15-23 02:30PM	The 3 Most Undervalued Biotech Stocks to Buy in December (InvestorPlace)
Dec-12-23 03:05PM	Insider Sell: Chief Medical Officer Eiry Roberts Sells Shares of Neurocrine Biosciences Inc (GuruFocus.com)
Dec-10-23 11:15AM	Insider Sell Alert: Chief Legal Officer Darin Lippoldt Sells Shares of Neurocrine Biosciences Inc (GuruFocus.com)
Dec-09-23 11:05AM	Insider Sell: Chief Medical Officer Eiry Roberts Sells Shares of Neurocrine Biosciences Inc (GuruFocus.com)
Dec-06-23 03:01AM	Sosei Heptares' Partner Neurocrine Biosciences Confirms its Plans to Evaluate Two New Muscarinic Agonist Candidates in Phase 1 Clinical Studies (GlobeNewswire)
Dec-05-23 04:01PM	Neurocrine Biosciences Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Crinecerfont in Congenital Adrenal Hyperplasia (PR Newswire)
Dec-02-23 05:06AM	Insider Sell Alert: Chief Scientific Officer Jude Onyia Sells Shares of Neurocrine Biosciences Inc (GuruFocus.com)
Dec-01-23 07:00AM	Neurocrine Biosciences to Host Analyst Day on December 5, 2023 (PR Newswire)
Nov-30-23 05:04AM	Neurocrine Biosciences Inc's Chief Legal Officer Darin Lippoldt Sells Shares: An Insider Analysis (GuruFocus.com)
Nov-13-23 06:07PM	12 Best Low Beta Stocks To Buy (Insider Monkey)
07:00AM	Neurocrine Biosciences Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation (PR Newswire)
Nov-09-23 04:01PM	Neurocrine Biosciences Provides Development Pipeline Update (PR Newswire)
Nov-08-23 04:05PM	Neurocrine Biosciences Launches Interactive Digital Tool for use by Healthcare Providers to Help Expand Education on Identifying and Diagnosing Tardive Dyskinesia (PR Newswire)
04:01PM	Neurocrine Biosciences to Present at the Jefferies London Healthcare Conference (PR Newswire)
Nov-06-23 09:45AM	Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 08:30AM	Neurocrine Biosciences Presents INGREZZA (valbenazine) Capsules Interim Data Demonstrating Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 50 at Huntington Study Group 2023 (PR Newswire)
Nov-01-23 06:34PM	The Neurocrine Biosciences Inc (NBIX) Company: A Short SWOT Analysis (GuruFocus.com)
Oct-31-23 09:30AM	Neurocrine (NBIX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
08:32AM	Neurocrine Biosciences Inc (NBIX) Reports 29% YoY Growth in Q3 2023 Net Product Sales (GuruFocus.com)
08:15AM	Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates (Zacks)
07:05AM	Neurocrine: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Neurocrine Biosciences Reports Third Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance (PR Newswire)
Oct-24-23 10:00AM	Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-20-23 11:43AM	BEAM to Reprioritize Portfolio, Slash Jobs, Shares Tank (Zacks)
Oct-18-23 11:13AM	Lisata's (LSTA) Lead Cancer Drug Gets EC's Orphan Tag, Stock Up (Zacks)
Oct-16-23 12:53PM	Catalyst (CPRX) Seeks to Increase Maximum Daily Dose for Firdapse (Zacks)
Oct-10-23 04:01PM	Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2023 Financial Results (PR Newswire)

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BENEVICH ERIC	Chief Commercial Officer	Apr 15 '24	Option Exercise	81.21	19,818	1,609,431	53,365	Apr 17 05:19 PM
BENEVICH ERIC	Chief Commercial Officer	Apr 15 '24	Sale	133.36	19,818	2,643,020	40,778	Apr 17 05:19 PM
Delaet Ingrid	Chief Regulatory Officer	Apr 01 '24	Option Exercise	79.02	272	21,493	7,779	Apr 03 04:44 PM
Delaet Ingrid	Chief Regulatory Officer	Apr 01 '24	Sale	137.30	272	37,346	7,507	Apr 03 04:44 PM
Delaet Ingrid	Chief Regulatory Officer	Mar 21 '24	Option Exercise	103.52	5,000	517,600	12,507	Mar 25 06:02 PM
Delaet Ingrid	Chief Regulatory Officer	Mar 21 '24	Sale	145.06	5,000	725,320	7,507	Mar 25 06:02 PM
BENEVICH ERIC	Chief Commercial Officer	Mar 14 '24	Option Exercise	80.90	75,000	6,067,628	110,299	Mar 15 05:33 PM
MORROW GEORGE J	Director	Mar 14 '24	Option Exercise	39.79	40,000	1,591,600	20,000	Mar 15 05:25 PM
BENEVICH ERIC	Chief Commercial Officer	Mar 14 '24	Sale	139.38	75,000	10,453,417	40,778	Mar 15 05:33 PM
MORROW GEORGE J	Director	Mar 14 '24	Sale	139.42	40,000	5,576,710	0	Mar 15 05:25 PM
POPS RICHARD F	Director	Mar 13 '24	Option Exercise	42.76	23,200	992,032	52,712	Mar 15 05:19 PM
Delaet Ingrid	Chief Regulatory Officer	Mar 13 '24	Option Exercise	106.02	3,000	318,060	10,507	Mar 15 05:15 PM
POPS RICHARD F	Director	Mar 13 '24	Sale	140.33	23,200	3,255,621	29,512	Mar 15 05:19 PM
Delaet Ingrid	Chief Regulatory Officer	Mar 13 '24	Sale	140.14	3,000	420,419	7,507	Mar 15 05:15 PM
Delaet Ingrid	Chief Regulatory Officer	Mar 11 '24	Option Exercise	106.02	200	21,204	7,707	Mar 12 06:38 PM
POPS RICHARD F	Director	Mar 11 '24	Option Exercise	42.76	100	4,276	29,612	Mar 12 06:47 PM
Delaet Ingrid	Chief Regulatory Officer	Mar 11 '24	Sale	140.00	200	28,000	7,507	Mar 12 06:38 PM
POPS RICHARD F	Director	Mar 11 '24	Sale	140.00	100	14,000	29,512	Mar 12 06:47 PM
Delaet Ingrid	Chief Regulatory Officer	Mar 08 '24	Option Exercise	106.02	1,800	190,836	9,307	Mar 12 06:38 PM
POPS RICHARD F	Director	Mar 08 '24	Option Exercise	42.76	1,700	72,692	31,212	Mar 12 06:47 PM
Delaet Ingrid	Chief Regulatory Officer	Mar 08 '24	Sale	140.03	1,800	252,053	7,507	Mar 12 06:38 PM
POPS RICHARD F	Director	Mar 08 '24	Sale	140.05	1,700	238,078	29,512	Mar 12 06:47 PM
Delaet Ingrid	Chief Regulatory Officer	Feb 29 '24	Option Exercise	79.02	273	21,572	7,780	Feb 29 07:02 PM
Delaet Ingrid	Chief Regulatory Officer	Feb 29 '24	Sale	135.51	273	36,994	7,507	Feb 29 07:02 PM
BENEVICH ERIC	Chief Commercial Officer	Feb 28 '24	Option Exercise	53.67	75,000	4,025,043	93,759	Feb 29 06:55 PM
Delaet Ingrid	Chief Regulatory Officer	Feb 28 '24	Option Exercise	79.02	6,544	517,107	10,007	Feb 29 07:02 PM
BENEVICH ERIC	Chief Commercial Officer	Feb 28 '24	Sale	134.69	75,000	10,101,608	40,616	Feb 29 06:55 PM
Delaet Ingrid	Chief Regulatory Officer	Feb 28 '24	Sale	135.34	6,544	885,638	7,507	Feb 29 07:02 PM
Norwalk Leslie V	Director	Feb 27 '24	Option Exercise	84.95	8,000	679,600	8,000	Feb 29 06:50 PM
Norwalk Leslie V	Director	Feb 27 '24	Sale	135.67	8,000	1,085,388	0	Feb 29 06:50 PM
POPS RICHARD F	Director	Feb 20 '24	Option Exercise	12.98	15,000	194,700	44,512	Feb 22 05:11 PM
POPS RICHARD F	Director	Feb 20 '24	Sale	132.47	15,000	1,987,047	29,512	Feb 22 05:11 PM
GORMAN KEVIN CHARLES	Chief Executive Officer	Feb 13 '24	Option Exercise	39.28	5,090	199,951	512,052	Feb 14 05:17 PM
GORMAN KEVIN CHARLES	Chief Executive Officer	Feb 13 '24	Sale	133.02	2,832	376,700	514,596	Feb 15 05:43 PM
Boyer David W.	Chief Corp. Affairs Officer	Feb 13 '24	Sale	133.07	1,811	240,996	4,895	Feb 15 05:33 PM
Onyia Jude	Chief Scientific Officer	Feb 13 '24	Sale	132.94	1,432	190,371	13,128	Feb 15 05:48 PM
Gano Kyle	Chief Business Development Off	Feb 13 '24	Sale	132.89	1,352	179,674	135,166	Feb 15 05:40 PM
ABERNETHY MATT	Chief Financial Officer	Feb 13 '24	Sale	132.85	1,352	179,612	31,528	Feb 15 05:27 PM
ROBERTS EIRY	Chief Medical Officer	Feb 13 '24	Sale	132.96	1,114	148,122	23,716	Feb 15 05:51 PM
BENEVICH ERIC	Chief Commercial Officer	Feb 13 '24	Sale	133.01	1,098	146,050	40,616	Feb 15 05:29 PM
Lippoldt Darin	Chief Legal Officer	Feb 13 '24	Sale	132.99	1,098	146,028	39,740	Feb 15 05:45 PM
Cooke Julie	Chief Human Resources Officer	Feb 13 '24	Sale	133.04	796	105,902	17,976	Feb 15 05:35 PM
Delaet Ingrid	Chief Regulatory Officer	Feb 13 '24	Sale	133.03	716	95,253	7,507	Feb 15 05:38 PM
GORMAN KEVIN CHARLES	Chief Executive Officer	Feb 08 '24	Sale	134.15	2,274	305,052	506,962	Feb 08 07:21 PM
Cooke Julie	Chief Human Resources Officer	Feb 08 '24	Sale	135.44	1,329	179,995	17,263	Feb 08 07:35 PM
Boyer David W.	Chief Corp. Affairs Officer	Feb 08 '24	Sale	135.41	1,328	179,830	4,895	Feb 08 07:46 PM
ABERNETHY MATT	Chief Financial Officer	Feb 08 '24	Sale	134.21	980	131,529	30,314	Feb 08 07:12 PM
ROBERTS EIRY	Chief Medical Officer	Feb 08 '24	Sale	134.21	980	131,522	22,717	Feb 08 07:28 PM
Gano Kyle	Chief Business Development Off	Feb 08 '24	Sale	134.20	980	131,519	133,952	Feb 08 07:17 PM
BENEVICH ERIC	Chief Commercial Officer	Feb 08 '24	Sale	134.19	980	131,509	39,631	Feb 08 07:15 PM
Lippoldt Darin	Chief Legal Officer	Feb 08 '24	Sale	134.24	911	122,289	38,755	Feb 08 07:25 PM
GORMAN KEVIN CHARLES	Chief Executive Officer	Feb 06 '24	Sale	142.18	3,040	432,218	504,919	Feb 08 07:21 PM
Gano Kyle	Chief Business Development Off	Feb 06 '24	Sale	142.20	1,600	227,522	133,072	Feb 08 07:17 PM
ABERNETHY MATT	Chief Financial Officer	Feb 06 '24	Sale	142.19	1,280	182,000	29,434	Feb 08 07:12 PM
BENEVICH ERIC	Chief Commercial Officer	Feb 06 '24	Sale	142.12	1,280	181,910	38,751	Feb 08 07:15 PM
Cooke Julie	Chief Human Resources Officer	Feb 06 '24	Sale	142.07	1,215	172,617	17,263	Feb 08 07:35 PM
ROBERTS EIRY	Chief Medical Officer	Feb 06 '24	Sale	142.24	1,121	159,446	21,837	Feb 08 07:28 PM
Lippoldt Darin	Chief Legal Officer	Feb 06 '24	Sale	142.17	1,041	147,995	37,939	Feb 08 07:25 PM
Boyer David W.	Chief Corp. Affairs Officer	Feb 06 '24	Sale	141.96	456	64,734	4,894	Feb 08 07:46 PM
Delaet Ingrid	Chief Regulatory Officer	Feb 01 '24	Sale	139.77	623	87,077	6,865	Feb 02 07:14 PM
GORMAN KEVIN CHARLES	Chief Executive Officer	Jan 31 '24	Sale	140.69	2,707	380,845	502,188	Feb 02 07:21 PM
Boyer David W.	Chief Corp. Affairs Officer	Jan 31 '24	Sale	140.80	2,096	295,115	4,894	Feb 02 07:07 PM
Cooke Julie	Chief Human Resources Officer	Jan 31 '24	Sale	141.29	1,740	245,842	17,263	Feb 02 07:11 PM
Gano Kyle	Chief Business Development Off	Jan 31 '24	Sale	140.70	1,541	216,813	131,635	Feb 02 07:17 PM
ROBERTS EIRY	Chief Medical Officer	Jan 31 '24	Sale	140.79	1,457	205,132	20,832	Feb 02 07:29 PM
ABERNETHY MATT	Chief Financial Officer	Jan 31 '24	Sale	140.72	1,283	180,539	28,284	Feb 02 07:00 PM
Lippoldt Darin	Chief Legal Officer	Jan 31 '24	Sale	140.65	1,250	175,810	37,005	Feb 02 07:24 PM
BENEVICH ERIC	Chief Commercial Officer	Jan 31 '24	Sale	140.78	1,207	169,927	37,601	Feb 02 07:05 PM
Delaet Ingrid	Chief Regulatory Officer	Jan 31 '24	Sale	141.94	422	59,899	6,309	Feb 02 07:14 PM
Onyia Jude	Chief Scientific Officer	Jan 31 '24	Sale	141.94	126	17,884	11,843	Feb 02 07:26 PM
Lippoldt Darin	Chief Legal Officer	Jan 22 '24	Option Exercise	79.02	10,000	790,200	45,882	Jan 24 05:47 PM
Lippoldt Darin	Chief Legal Officer	Jan 22 '24	Sale	139.86	10,000	1,398,553	35,882	Jan 24 05:47 PM
GORMAN KEVIN CHARLES	Chief Executive Officer	Jan 09 '24	Option Exercise	19.59	62,023	1,215,031	561,777	Jan 10 04:31 PM
GORMAN KEVIN CHARLES	Chief Executive Officer	Jan 09 '24	Sale	134.01	62,023	8,311,895	499,754	Jan 10 04:31 PM
GORMAN KEVIN CHARLES	Chief Executive Officer	Jan 08 '24	Option Exercise	19.59	105,835	2,073,308	605,589	Jan 10 04:31 PM
GORMAN KEVIN CHARLES	Chief Executive Officer	Jan 08 '24	Sale	132.44	105,835	14,016,523	499,754	Jan 10 04:31 PM
Gano Kyle	Chief Business Development Off	Jan 02 '24	Option Exercise	19.59	75,000	1,469,250	199,134	Jan 04 06:32 PM
RASTETTER WILLIAM H	Director	Jan 02 '24	Option Exercise	12.98	20,000	259,600	62,785	Jan 04 06:26 PM
Gano Kyle	Chief Business Development Off	Jan 02 '24	Sale	131.47	75,000	9,860,194	130,250	Jan 04 06:32 PM
RASTETTER WILLIAM H	Director	Jan 02 '24	Sale	131.47	11,044	1,451,927	51,741	Jan 04 06:26 PM
Cooke Julie	Chief Human Resources Officer	Dec 22 '23	Option Exercise	73.04	24,000	1,752,900	31,263	Dec 27 04:08 PM
Cooke Julie	Chief Human Resources Officer	Dec 22 '23	Sale	128.66	24,000	3,087,808	17,263	Dec 27 04:08 PM
LYONS GARY A	Director	Dec 22 '23	Sale	130.04	10,000	1,300,443	193,697	Dec 27 04:10 PM
ROBERTS EIRY	Chief Medical Officer	Dec 22 '23	Sale	126.74	10,000	1,267,448	19,521	Dec 27 04:15 PM
ROBERTS EIRY	Chief Medical Officer	Dec 12 '23	Option Exercise	81.05	13,925	1,128,621	36,499	Dec 14 05:22 PM
ROBERTS EIRY	Chief Medical Officer	Dec 12 '23	Sale	120.30	13,925	1,675,240	29,521	Dec 14 05:22 PM
ROBERTS EIRY	Chief Medical Officer	Dec 08 '23	Option Exercise	81.05	300	24,315	29,721	Dec 11 06:18 PM
ROBERTS EIRY	Chief Medical Officer	Dec 08 '23	Sale	120.10	300	36,031	29,521	Dec 11 06:18 PM
ROBERTS EIRY	Chief Medical Officer	Dec 07 '23	Option Exercise	78.52	77,379	6,076,120	68,243	Dec 11 06:18 PM
ROBERTS EIRY	Chief Medical Officer	Dec 07 '23	Sale	120.37	77,379	9,314,319	29,521	Dec 11 06:18 PM
Lippoldt Darin	Chief Legal Officer	Dec 06 '23	Option Exercise	43.24	20,830	900,689	56,712	Dec 08 06:23 PM
ROBERTS EIRY	Chief Medical Officer	Dec 06 '23	Option Exercise	77.81	8,396	653,293	37,917	Dec 08 07:09 PM
Lippoldt Darin	Chief Legal Officer	Dec 06 '23	Sale	119.86	20,830	2,496,648	35,882	Dec 08 06:23 PM
ROBERTS EIRY	Chief Medical Officer	Dec 06 '23	Sale	120.03	8,396	1,007,780	29,521	Dec 08 07:09 PM
LYONS GARY A	Director	Dec 01 '23	Option Exercise	12.98	5,000	64,900	208,697	Dec 05 04:54 PM
LYONS GARY A	Director	Dec 01 '23	Sale	116.77	5,000	583,837	203,697	Dec 05 04:54 PM
Onyia Jude	Chief Scientific Officer	Nov 29 '23	Sale	113.57	2,331	264,733	11,732	Dec 01 05:41 PM
Lippoldt Darin	Chief Legal Officer	Nov 27 '23	Sale	112.27	10,919	1,225,911	35,882	Nov 29 04:36 PM
Boyer David W.	Chief Corp. Affairs Officer	Oct 02 '23	Sale	112.68	1,437	161,921	4,894	Oct 04 05:07 PM
LYONS GARY A	Director	Sep 12 '23	Option Exercise	12.98	5,000	64,900	208,697	Sep 14 04:51 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

GMED

Globus Medical Inc

NBIX

Neurocrine Biosciences, Inc.

Upgrade your FINVIZ experience